Molecular Glue Degraders in Early Development for Cancer Therapy
Medicinal Research Reviews · 07.09.2026
DOI: 10.1002/med.70104 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Medicinal Research Reviews, online erschienen am 07.09.2026. Verfasst von E Sila Ozdemir und 4 weiteren Autor:innen. Beteiligte Einrichtung: Independent Researcher, Seattle, Washington, USA. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 87 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, Science and Technology Research Council of Tu, National Cancer Institute.
Abstract (Originalsprache)
Molecular glue degraders are an emerging class of small molecule allosteric modulators that induce or stabilize protein‐protein interactions, enabling targeted degradation of previously intractable proteins. By redirecting E3 ligases to recognize neosubstrates, proteins that are not typically recognized by a specific E3 ubiquitin ligase, they expand the scope of drug discovery beyond traditional paradigms. We review mechanistic principles underlying molecular glue activity, including cooperativity, weak affinity interactions, structural degrons, and higher‐order complex formation. We discuss discovery strategies, from serendipitous identification to emerging rational and chemoproteomic approaches, and key E3 ligase systems with relevance to oncology. We highlight clinical and preclinical applications, alongside challenges such as resistance mechanisms, context‐dependent activity, and limitations in predicting neosubstrates. Molecular glues are transitioning from serendipitous discoveries to a mechanism‐driven therapeutic platform. Progress depends on integrating structural biology, proteomics, and computational modeling to enable rational design and improve predictability. Expanding the repertoire of E3 ligases and understanding context‐specific degradation will be critical to fully realize their potential in oncology and beyond.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Independent Researcher, Seattle, Washington, USA.
- Biophysics and Computational Biology Section, Frederick National Laboratory for Cancer Research in the Cancer Innovation Laboratory, National Cancer Institute, Frederick, Maryland, USA.
- Department of Chemical and Biological Engineering, Koc University, Istanbul, Turkey.
- Department of Computer Engineering, Koc University, Istanbul, Turkey.
- Department of Human Molecular Genetics and Biochemistry, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
ORCID-Profile: E Sila Ozdemir, Hyunbum Jang, Attila Gursoy, Ruth Nussinov
Förderung
- NCI NIH HHS
- Science and Technology Research Council of Tu
- National Cancer Institute
Zitieren
APA
Ozdemir, E. S., Jang, H., Keskin, O., Gursoy, A., & Nussinov, R. (2026). Molecular Glue Degraders in Early Development for Cancer Therapy. Medicinal Research Reviews. https://doi.org/10.1002/med.70104
Vancouver
Ozdemir ES, Jang H, Keskin O, Gursoy A, Nussinov R. Molecular Glue Degraders in Early Development for Cancer Therapy. Medicinal Research Reviews. 2026. doi:10.1002/med.70104
BibTeX
@article{Ozdemir2026,
author = {Ozdemir, E Sila and Jang, Hyunbum and Keskin, Ozlem and Gursoy, Attila and Nussinov, Ruth},
title = {Molecular Glue Degraders in Early Development for Cancer Therapy},
journal = {Medicinal Research Reviews},
year = {2026},
doi = {10.1002/med.70104}
}
EUVIMED